First GMP-compliant Treg cellular product released from new Poltreg’s Plant!

2023-11-27

First GMP-compliant Treg cellular product released from new Poltreg’s Plant!

Poltreg is under certification of its new plant. Today is a big day – we released successfully first GMP-
compliant Tregs cellular product from the unit 1. Everything is up and running for routine
manufacturing. Congratulation to the team!

In the facility we can manufacture around 1500 products yearly – all we need for our ongoing trials
and commercial hospital-exemption activities. There is also a space to our antigen-specific, CAR and
TCR-engineered Tregs and CDMO work. R&D labs, where we work on new ideas and products, are
also located in the facility.

See other news

2024-09-16

China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis

See

2024-09-11

Join us for the PolTREG H1 2024 financial results webinar!

See

2024-09-09

PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence

See

2024-07-24

The European Medicines Agency has granted PolTREG preliminary approval to launch a new Phase 2 clinical trial in presymptomatic Type-1 Diabetes.

See

2024-06-25

PolTREG will get access to new groups of type-1 diabetes patients with its Treg cellulartherapies after signing a cooperation deal with the University Clinical Center in Gdansk

See

2024-06-24

Positive results of a long-term safety and efficacy study of PTG-007 in early-onset type-1 diabetes

See

2024-06-13

PolTREG received approval to operate a genetic engineering facility from Poland’s ministry of Climate and Environment

See

2024-05-14

PolTREG received a patent in the US protecting the manufacturing of T-regulatory cells to treat Type-1 Diabetes, and ways the therapy is administered

See

First GMP-compliant Treg cellular product released from new Poltreg’s Plant!

See other news

About Us

Our Science

Patients